Galera Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	149.04	149.05	-18.96	-59.08	-62.22	-80.53
Depreciation & Amortization	-	-	0.02	0.26	0.11	0.78
Loss (Gain) From Sale of Assets	-3.5	-3.5	0.05	-0.07	-	-
Asset Writedown & Restructuring Costs	-	-	6.98	-	-	-
Stock-Based Compensation	0.35	0.41	2.55	5.56	7.16	7.23
Other Operating Activities	-151.05	-151.34	-0.66	11.41	11.5	7.19
Change in Accounts Payable	-0.05	-1.01	-1.42	-2.21	-1.46	-0.1
Change in Other Net Operating Assets	0.52	0.35	-0.71	-0.72	1.48	-2.53
Operating Cash Flow	-4.69	-6.05	-12.15	-44.85	-43.43	-67.96
Capital Expenditures	-	-	-	-0.06	-0.03	-0.28
Sale of Property, Plant & Equipment	3.5	3.5	0	-	-	-
Cash Acquisitions	-	-	-0.05	-	-	-
Investment in Securities	-	-	-	27.35	24.02	5.52
Investing Cash Flow	3.5	3.5	-0.05	27.29	23.99	5.24
Long-Term Debt Issued	-	-	-	-	-	57.5
Net Debt Issued (Repaid)	-	-	-	-	-	57.5
Issuance of Common Stock	-	0.64	2.22	31.5	3.89	9.21
Financing Cash Flow	-	0.64	2.22	31.5	3.89	66.71
Net Cash Flow	-1.19	-1.91	-9.97	13.94	-15.54	3.99
Free Cash Flow	-4.69	-6.05	-12.15	-44.91	-43.45	-68.24
Free Cash Flow Per Share	-0.05	-0.06	-0.22	-1.01	-1.60	-2.65
Levered Free Cash Flow	-2.76	-3.4	-7.78	-35.66	-32.1	-44.7
Unlevered Free Cash Flow	-2.76	-3.4	-7.78	-28.53	-24.87	-40.2
Change in Working Capital	0.48	-0.67	-2.13	-2.93	0.02	-2.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.